CA3132578A1 - Method for producing influenza ha split vaccine - Google Patents

Method for producing influenza ha split vaccine Download PDF

Info

Publication number
CA3132578A1
CA3132578A1 CA3132578A CA3132578A CA3132578A1 CA 3132578 A1 CA3132578 A1 CA 3132578A1 CA 3132578 A CA3132578 A CA 3132578A CA 3132578 A CA3132578 A CA 3132578A CA 3132578 A1 CA3132578 A1 CA 3132578A1
Authority
CA
Canada
Prior art keywords
influenza
split vaccine
vaccine
split
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3132578A
Other languages
English (en)
French (fr)
Inventor
Yoshimasa Takahashi
Yu Adachi
Manabu ATO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Infectious Diseases
Sumitomo Pharma Co Ltd
Original Assignee
National Institute of Infectious Diseases
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Infectious Diseases, Sumitomo Dainippon Pharma Co Ltd filed Critical National Institute of Infectious Diseases
Publication of CA3132578A1 publication Critical patent/CA3132578A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA3132578A 2019-03-04 2020-03-03 Method for producing influenza ha split vaccine Pending CA3132578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-038662 2019-03-04
JP2019038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (1)

Publication Number Publication Date
CA3132578A1 true CA3132578A1 (en) 2020-09-10

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3132578A Pending CA3132578A1 (en) 2019-03-04 2020-03-03 Method for producing influenza ha split vaccine

Country Status (15)

Country Link
US (1) US12491240B2 (enExample)
EP (1) EP3936147A4 (enExample)
JP (1) JP7545955B2 (enExample)
KR (1) KR20210135261A (enExample)
CN (1) CN114096273A (enExample)
AU (1) AU2020233456A1 (enExample)
BR (1) BR112021017310A8 (enExample)
CA (1) CA3132578A1 (enExample)
EA (1) EA202192398A1 (enExample)
IL (1) IL285984A (enExample)
MX (1) MX2021010685A (enExample)
MY (1) MY208974A (enExample)
PH (1) PH12021552094A1 (enExample)
SG (1) SG11202109566XA (enExample)
WO (1) WO2020179797A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
KR20220098370A (ko) * 2019-11-07 2022-07-12 세퀴러스 유케이 리미티드 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법
AU2024264265A1 (en) * 2023-04-26 2025-11-13 Japan Institute For Health Security Anti-influenza antibody

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
US20230201329A1 (en) * 2006-07-17 2023-06-29 Glaxosmithkline Biologicals Sa Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
RU2553325C2 (ru) 2008-07-25 2015-06-10 Институт Фо Ресёч Ин Биомедицин Нейтрализующие антитела против вируса гриппа а и их использование
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
JP5762969B2 (ja) * 2008-11-25 2015-08-12 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ ｐＨ安定性のエンベロープ付きウィルスの生産方法
CN101524538A (zh) 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
WO2011103453A2 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP2860190A3 (en) 2010-03-08 2015-07-15 Celltrion, Inc. Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
JP6232373B2 (ja) 2011-04-21 2017-11-15 ナノセラピューティクス・インコーポレイテッドＮａｎｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ワクチンから抗原を単離し定量する方法
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
CN104302317B (zh) * 2012-05-16 2016-07-06 Kj生物科学有限公司 新型和改进的流感疫苗
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN106794241A (zh) 2014-08-18 2017-05-31 圣诺菲·帕斯图尔公司 烷基化流感疫苗
AU2015373928B2 (en) 2014-12-31 2019-10-17 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
WO2016178811A1 (en) * 2015-05-04 2016-11-10 Epivax, Inc. Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
DK3355933T3 (da) * 2015-09-29 2020-07-20 Sumitomo Dainippon Pharma Co Ltd Adeninkonjugatforbindelser og deres anvendelse som vaccineadjuvanser
ES3039485T3 (en) * 2017-03-29 2025-10-21 Sumitomo Pharma Co Ltd Vaccine adjuvant formulation
JP7403733B2 (ja) * 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
TW202011986A (zh) * 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
BR112021011495A8 (pt) * 2018-12-26 2022-12-06 Sumitomo Dainippon Pharma Co Ltd Preparação incluindo adjuvante para vacina
WO2020176524A1 (en) * 2019-02-28 2020-09-03 Novavax, Inc. Methods for preventing disease or disorder caused by rsv infection

Also Published As

Publication number Publication date
KR20210135261A (ko) 2021-11-12
CN114096273A (zh) 2022-02-25
IL285984A (en) 2021-10-31
AU2020233456A1 (en) 2021-10-07
JP7545955B2 (ja) 2024-09-05
BR112021017310A8 (pt) 2022-12-06
EP3936147A4 (en) 2022-09-28
US20220152191A1 (en) 2022-05-19
US12491240B2 (en) 2025-12-09
SG11202109566XA (en) 2021-10-28
EP3936147A1 (en) 2022-01-12
EA202192398A1 (ru) 2021-11-23
MY208974A (en) 2025-06-14
BR112021017310A2 (enExample) 2021-11-16
MX2021010685A (es) 2021-12-10
WO2020179797A1 (ja) 2020-09-10
PH12021552094A1 (en) 2022-05-30
JPWO2020179797A1 (enExample) 2020-09-10

Similar Documents

Publication Publication Date Title
US20230346911A1 (en) Broadly protective influenza b virus vaccines
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
US7842295B2 (en) Canine influenza virus and related compositions and methods of use
US11732031B2 (en) Method for producing influenza HA split vaccine
CN107365751A (zh) 流感疫苗的生产
WO2015183969A1 (en) Stabilized influenza hemagglutinin stem region trimers and uses thereof
IL303650B1 (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
US12491240B2 (en) Method for producing influenza HA split vaccine
JP2002532435A (ja) Ｒｓｖサブユニット成分およびインフルエンザウイルス調製物を含む多価免疫原性組成物
US20230406910A1 (en) Method for producing influenza ha split vaccine
JP7203015B2 (ja) 免疫原性組成物
US9198965B2 (en) Peptide adjuvant for influenza vaccination
TWI857017B (zh) 流感ha裂解疫苗之製造方法
HK40068192A (en) Method for preparing influenza ha split vaccine
EA045912B1 (ru) Способ приготовления сплит-вакцины на основе гемагглютинина гриппа
JP2024522193A (ja) 免疫原としての広範囲反応性ウイルス抗原、その組成物及び使用方法
HK40032891A (en) Method for producing influenza ha split vaccine
EA045852B1 (ru) Способ получения сплит-вакцины с ha гриппа
JP2023515829A (ja) 小児対象のための高用量インフルエンザワクチン

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240229